文献速递心脏核医学

熊去氧胆酸促进99mTc-MIBI心肌灌注显像早期肝脏清除的随机双盲安慰剂对照试验

Effect of ursodeoxycholic acid in facilitating early hepatic clearance of radiotracer among patients undergoing 99mTc-sestamibi myocardial perfusion scintigraphy: A randomized double blind placebo controlled parallel trial.
PubMed 文献 · J Nucl Cardiol · 2019-01-29

该前瞻性随机双盲安慰剂对照试验纳入120例转诊行腺苷负荷或存活心肌MPS的患者,1:1随机接受UDCA或安慰剂。118例完成研究,UDCA组在腺苷负荷MPS中30和60分钟肝脏计数显著降低、心肌/肝脏比值改善,存活心肌MPS组60分钟肝脏计数有边缘显著改变,图像质量更优。结论认为UDCA可加速肝脏示踪剂清除,提供更早且更好的图像。

要点

  • UDCA组腺苷负荷MPS在30和60分钟肝脏计数显著降低,心肌/肝脏比值改善。
  • 存活心肌MPS组UDCA在60分钟肝脏计数仅呈边缘显著改变。
  • UDCA干预使MPS图像质量更优并可能缩短等待扫描时间。

核心结论

  • UDCA干预通过加速肝脏示踪剂清除,使MPS获得更早且更好的图像。

研究设计与样本

  • 前瞻性、随机双盲、安慰剂对照平行临床试验,120例转诊行腺苷负荷或存活心肌MPS的患者按1:1随机接受UDCA或安慰剂。
  • 118例参与者(59±11.9岁;84名男性)完成研究,UDCA组60例、安慰剂组58例。

主要发现

  • 腺苷负荷MPS组接受UDCA后30和60分钟肝脏计数显著降低,心肌/肝脏比值改善。
  • 存活心肌MPS组接受UDCA后60分钟肝脏计数呈边缘显著改变。
  • UDCA组图像质量更优,可能减少等待扫描时间。

临床怎么用

  • 对需行99mTc-MIBI MPS且存在持续肝脏活性干扰的患者,可考虑UDCA以促进早期肝脏清除、改善图像判读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infra-cardiac tracer activity due to persistent hepatic activity interferes in inferior and infero-septal wall assessment during 99mTc-MIBI SPECT/CT myocardial perfusion scintigraphy (MPS) in evaluation of patients with coronary artery disease. It affects image interpretation with increased study duration. Ursodeoxycholic acid (UDCA) is known to enhance hepatic excretion of bilirubin and bile salts, though its role in enhancing the hepatic tracer clearance in facilitating cardiac imaging is not known. METHODS: This prospective, randomized double-blind, placebo controlled clinical trial of 120 patients, referred for adenosine stress or viability MPS studies were randomized 1:1 to receive either UDCA or placebo. Outcome was quantitative & qualitative improvement in imaging for better interpretation and to reduce the waiting time for scan. RESULTS: 118 participants (59 ± 11.9 years; 84 men) underwent adenosine stress MPS or viability MPS. Sixty participants had UDCA while 58 had placebo intervention. The study showed significant decrease in liver counts with improved myocardial to liver ratio at 30 and 60 minutes in adenosine stress MPS group, and marginally significant alteration in liver counts at 60 minutes in viability MPS group receiving UDCA, resulting in better images. CONCLUSION: UDCA intervention in MPS provides early and better image due to faster hepatic tracer clearance.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Sood A, Singh D, Dutta U, et al. Effect of ursodeoxycholic acid in facilitating early hepatic clearance of radiotracer among patients undergoing 99mTc-sestamibi myocardial perfusion scintigraphy: A randomized double blind placebo controlled parallel trial. J Nucl Cardiol. 2019. PMID: 30697661. doi:10.1007/s12350-019-01597-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。